PET/CT Evaluation of Treatment Response in Breast Cancer
Status: | Terminated |
---|---|
Conditions: | Breast Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/21/2016 |
Start Date: | October 2010 |
End Date: | April 2015 |
Positron Emission Tomography (PET)-Computed Tomography (CT) PET/CT Evaluation of Treatment Response in Breast Cancer
The purpose of this study is to develop Positron Emission Tomography (PET) - Computed
Tomography (CT) PET/CT imaging methods for looking at the effects of chemotherapy in breast
cancer.
Tomography (CT) PET/CT imaging methods for looking at the effects of chemotherapy in breast
cancer.
Inclusion Criteria
- Subjects must have histologically proven breast cancer
- Subjects are being considered for preoperative chemotherapy
- Subjects must be ≥ 18 years old. Sensor Sub-Study Only
- Palpable subcutaneous or known disease with one surface <1cm below surface of skin.
- A subset of patients who have a mass located on any surface of the breast that is
accessible for Lucerno sensor placement will have additional testing.
Exclusion Criteria
- Children will be excluded from this study.
- Pregnant women and women who are breast feeding will be excluded from this study.
(The Vanderbilt University Medical Center radiology "PET Procedure Screening Form"
will be used to identify and exclude subjects who are pregnant or breastfeeding. A
urine pregnancy test/or serum beta HCG will also be performed for women of child
bearing potential).
- Patients who are acutely ill who are deemed by their treating physician as not
suitable candidates for this study.
- Intraluminal lesions will be excluded from the sensor sub-study.
- Non biopsy proven malignancy will be excluded from this study.
- Palpable subcutaneous or known disease with one surface >1cm below surface of skin
will be excluded from the sensor sub-study.
- Draining or exposed malignant tumor will be excluded from the sensor sub-study.
We found this trial at
1
site
Vanderbilt-Ingram Cancer Center The Vanderbilt-Ingram Cancer Center, located in Nashville, Tenn., brings together the clinical...
Click here to add this to my saved trials